TLL-018 tablets
Sponsors
Hangzhou Highlightll Pharmaceutical Co., Ltd
Conditions
Atopic Dermatitis (AD)Chronic Spontaneous UrticariaChronic Spontaneous Urticaria (CSU)
Phase 2
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
Not yet recruitingNCT07764003
Start: 2026-09-10End: 2027-12-31Target: 140Updated: 2026-08-24
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
Not yet recruitingNCT07784816
Start: 2026-08-31End: 2029-09-30Target: 390Updated: 2026-08-25